Physician profile
Jun Shoji
NPI 1942524483
$5,658.86
in general payments reported to CMS, 2019-2025
14 companies · $1,967 in 2025
The $1,967 reported for 2025 was more than what 89% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,208 · 2020: $347 · 2021: $85.15 · 2022: $300 · 2023: $214 · 2024: $537 · 2025: $1,967.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,618 · Travel and Lodging: $939 · Education: $161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,618.26 |
| Travel and Lodging | $939.04 |
| Education | $160.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $1,368.73 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $964.59 | 2019 | |
| Pfizer INC. | $816.81 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $709.60 | 2019-2022 | |
| Veloxis Pharmaceuticals, INC. | $458.58 | 2022-2025 | Envarsus |
| E.R. Squibb & Sons, L.L.C. | $271.30 | 2019-2024 | Nulojix |
| Alexion Pharmaceuticals, INC. | $223.03 | 2024-2025 | Ultomiris, Soliris |
| Cormedix INC. | $210.72 | 2024-2025 | Defencath, Defencath |
| Genzyme Corporation | $149.91 | 2025 | |
| Travere Therapeutics, INC. | $126.91 | 2023 | |
| Merck Sharp & Dohme LLC | $121.44 | 2025 | Prevymis |
| Kamada LTD. | $92.77 | 2023-2025 | |
| Apellis Pharmaceuticals, INC. | $86.78 | 2025 | Empaveli |
| Takeda Pharmaceuticals U.S.A., INC. | $57.69 | 2023-2024 | Livtencity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jun Shoji listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.